skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Remetinostat (Code C97513)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Remetinostat

Definition: A topical formulation containing the histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Upon cutaneous administration, SHP-141 selectively binds to and inhibits HDAC, resulting in an accumulation of highly acetylated histones in the skin (dermis and epidermis), the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes. These events may result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins. Topical administration of SHP-141 allows for high concentrations of this agent locally while minimizing systemic toxicity.

Display Name: Remetinostat

Label: Remetinostat

NCI Thesaurus Code: C97513 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL430257  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Methylparaben Suberohydroxamic Acid Phenyl Ester
Methyl 4-((8-(Hydroxyamino)-8-Oxooctanoyl)oxy)benzoate

External Source Codes: 
FDA UNII Code 37NT056AT4
ChEBI ID 946150-57-8 (see ChEBI info)
PDQ Closed Trial Search ID 703816
PDQ Open Trial Search ID 703816 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C97513
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom